Michael McDonald is a partner in the London office.
Mr. McDonald advises on all types of mergers and acquisitions, as well as joint ventures and restructurings. He has represented corporates, financial institutions and private equity funds on a broad range of public and private M&A transactions in various sectors, often involving cross-border issues. Mr. McDonald is recognized by Chambers UK
and The Legal 500
as a leading UK M&A and private equity lawyer.
Mr. McDonald joined the firm in August 2006 as a partner. His recent experience includes acting for Agilent in its acquisition of Danish-based cancer diagnostics company Dako from EQT, Amgen in its acquisition of Mustafa Nevzat Pharmaceuticals (MN) the Turkish biotech company, Dexia SA in the sale of its 50% stake in RBC Dexia Investor Services Limited to Royal Bank of Canada, Stanley Black & Decker in its acquisition of Niscayah, and Truvo in its global restructuring. Since joining the firm he also advised JC Flowers in the sale of NIBC to Kaupthing as well as the acquisition of Fidea, 3M Company in its public takeovers of Biotrace International plc and E Wood Holdings plc, UTC in its acquisition of Rentokil’s global security division, Istithmar in its investment in Pension Insurance Corporation, Riverdeep Holdings plc and GLG, and Airline Partners Australia on its takeover offer for Qantas. Prior to joining the firm, Mr. McDonald was an English qualified M&A partner at Allen & Overy in London. He received a law degree and M.B.A. from Dalhousie University in Halifax in 1991 and received an undergraduate degree in political science from the University of Alberta in 1987.
He is qualified as a solicitor in England and Wales and is admitted to practice law in the Province of Ontario.